| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 32 | 2026 | 638 | 4.620 |
Why?
|
| Carcinoma, Squamous Cell | 26 | 2025 | 762 | 2.380 |
Why?
|
| Receptor, Notch1 | 9 | 2026 | 76 | 2.300 |
Why?
|
| Mouth Neoplasms | 4 | 2024 | 94 | 1.810 |
Why?
|
| NF-E2-Related Factor 2 | 6 | 2025 | 130 | 1.390 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2025 | 265 | 1.170 |
Why?
|
| Cisplatin | 8 | 2025 | 273 | 0.910 |
Why?
|
| Cell Line, Tumor | 29 | 2026 | 3722 | 0.890 |
Why?
|
| Tumor Suppressor Protein p53 | 10 | 2025 | 733 | 0.890 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2025 | 819 | 0.840 |
Why?
|
| Papillomavirus Infections | 7 | 2024 | 384 | 0.790 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2022 | 25 | 0.760 |
Why?
|
| Lymphatic Metastasis | 1 | 2024 | 427 | 0.760 |
Why?
|
| Glutathione Peroxidase | 1 | 2022 | 48 | 0.750 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2025 | 2027 | 0.740 |
Why?
|
| Signal Transduction | 12 | 2026 | 4672 | 0.730 |
Why?
|
| Mutation | 17 | 2025 | 6147 | 0.720 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2025 | 617 | 0.710 |
Why?
|
| Cell Cycle Proteins | 9 | 2025 | 701 | 0.700 |
Why?
|
| Neovascularization, Pathologic | 4 | 2015 | 228 | 0.680 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 1796 | 0.610 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 131 | 0.600 |
Why?
|
| Tumor Microenvironment | 8 | 2026 | 705 | 0.600 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2021 | 224 | 0.560 |
Why?
|
| Apoptosis | 13 | 2025 | 1852 | 0.520 |
Why?
|
| DNA Copy Number Variations | 4 | 2020 | 1031 | 0.470 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2025 | 344 | 0.460 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2017 | 36 | 0.430 |
Why?
|
| Myeloid Cells | 1 | 2015 | 112 | 0.430 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 110 | 0.420 |
Why?
|
| Thiophenes | 2 | 2017 | 68 | 0.420 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2026 | 201 | 0.410 |
Why?
|
| Urea | 2 | 2017 | 222 | 0.400 |
Why?
|
| DNA Damage | 5 | 2021 | 520 | 0.380 |
Why?
|
| DNA Methylation | 3 | 2015 | 1099 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2025 | 1001 | 0.370 |
Why?
|
| Mice | 22 | 2026 | 18273 | 0.370 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1550 | 0.370 |
Why?
|
| Humans | 56 | 2026 | 130959 | 0.350 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 46 | 0.350 |
Why?
|
| Protein Kinases | 1 | 2013 | 319 | 0.350 |
Why?
|
| Chemokines, CXC | 2 | 2015 | 36 | 0.330 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 902 | 0.330 |
Why?
|
| Cell Proliferation | 13 | 2022 | 2475 | 0.320 |
Why?
|
| Animals | 29 | 2026 | 34000 | 0.310 |
Why?
|
| Checkpoint Kinase 1 | 4 | 2020 | 29 | 0.310 |
Why?
|
| Mice, Nude | 11 | 2025 | 706 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 5 | 2017 | 385 | 0.290 |
Why?
|
| Phosphoproteins | 1 | 2011 | 430 | 0.280 |
Why?
|
| Piperidines | 3 | 2020 | 232 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2025 | 591 | 0.270 |
Why?
|
| Tongue Neoplasms | 3 | 2015 | 31 | 0.270 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2020 | 60 | 0.270 |
Why?
|
| Radiation Tolerance | 2 | 2025 | 64 | 0.260 |
Why?
|
| Carcinoma | 4 | 2013 | 282 | 0.250 |
Why?
|
| Quinazolines | 3 | 2014 | 180 | 0.250 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 673 | 0.250 |
Why?
|
| Prognosis | 6 | 2024 | 4950 | 0.250 |
Why?
|
| Proteomics | 1 | 2011 | 606 | 0.250 |
Why?
|
| Pyrazoles | 6 | 2021 | 355 | 0.250 |
Why?
|
| Keratinocytes | 2 | 2025 | 73 | 0.240 |
Why?
|
| Paraffin Embedding | 1 | 2025 | 42 | 0.220 |
Why?
|
| Gain of Function Mutation | 2 | 2025 | 117 | 0.220 |
Why?
|
| Tissue Fixation | 1 | 2025 | 38 | 0.220 |
Why?
|
| Formaldehyde | 1 | 2025 | 51 | 0.220 |
Why?
|
| Chemotactic Factors | 1 | 2004 | 15 | 0.220 |
Why?
|
| Pyrimidines | 6 | 2020 | 451 | 0.220 |
Why?
|
| Homologous Recombination | 2 | 2021 | 99 | 0.210 |
Why?
|
| Thyroid Neoplasms | 3 | 2013 | 250 | 0.210 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2025 | 93 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1325 | 0.210 |
Why?
|
| Cigarette Smoking | 1 | 2025 | 95 | 0.200 |
Why?
|
| Pyrimidinones | 6 | 2021 | 63 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 1 | 2026 | 334 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 4 | 2015 | 1216 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2015 | 332 | 0.190 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 31 | 0.190 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 1619 | 0.190 |
Why?
|
| Nuclear Proteins | 4 | 2017 | 1215 | 0.190 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 61 | 0.190 |
Why?
|
| Dinoprostone | 1 | 2022 | 65 | 0.180 |
Why?
|
| Drug Synergism | 5 | 2025 | 236 | 0.180 |
Why?
|
| Calculi | 1 | 2022 | 13 | 0.180 |
Why?
|
| Dendritic Cells | 1 | 2004 | 435 | 0.180 |
Why?
|
| Cluster Analysis | 2 | 2014 | 417 | 0.180 |
Why?
|
| CREB-Binding Protein | 1 | 2021 | 55 | 0.180 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2021 | 50 | 0.180 |
Why?
|
| Rad51 Recombinase | 1 | 2021 | 32 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2020 | 259 | 0.170 |
Why?
|
| Histone Acetyltransferases | 1 | 2021 | 224 | 0.170 |
Why?
|
| S Phase | 2 | 2017 | 73 | 0.170 |
Why?
|
| Phosphorylation | 6 | 2017 | 1569 | 0.160 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2020 | 21 | 0.160 |
Why?
|
| Serpins | 3 | 2005 | 34 | 0.160 |
Why?
|
| Indazoles | 1 | 2020 | 35 | 0.160 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 3 | 2025 | 35 | 0.160 |
Why?
|
| Carcinogenesis | 2 | 2020 | 350 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 260 | 0.150 |
Why?
|
| Genomics | 4 | 2016 | 1623 | 0.150 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2004 | 39 | 0.150 |
Why?
|
| Papillomaviridae | 4 | 2022 | 178 | 0.150 |
Why?
|
| DNA, Mitochondrial | 1 | 2020 | 232 | 0.140 |
Why?
|
| Blotting, Western | 5 | 2014 | 1012 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2026 | 1922 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 5 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2017 | 53 | 0.130 |
Why?
|
| Databases, Genetic | 1 | 2020 | 507 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2017 | 59 | 0.130 |
Why?
|
| Baculoviridae | 4 | 2004 | 42 | 0.130 |
Why?
|
| Pteridines | 1 | 2017 | 10 | 0.130 |
Why?
|
| LIM Domain Proteins | 1 | 2017 | 66 | 0.130 |
Why?
|
| Male | 12 | 2026 | 64765 | 0.130 |
Why?
|
| Keratosis, Actinic | 1 | 2016 | 15 | 0.120 |
Why?
|
| Precancerous Conditions | 2 | 2016 | 280 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 427 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2020 | 1514 | 0.120 |
Why?
|
| Mitosis | 2 | 2014 | 185 | 0.120 |
Why?
|
| Disease Progression | 4 | 2016 | 2211 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 174 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 1625 | 0.120 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2015 | 11 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 20 | 0.110 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2015 | 49 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2909 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 56 | 0.110 |
Why?
|
| Cellular Senescence | 2 | 2014 | 216 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 567 | 0.110 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2011 | 12 | 0.110 |
Why?
|
| Mitochondria | 1 | 2020 | 764 | 0.110 |
Why?
|
| Mammary Glands, Human | 1 | 2015 | 81 | 0.110 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 3 | 2021 | 8 | 0.110 |
Why?
|
| Interleukin-8 | 2 | 2005 | 205 | 0.110 |
Why?
|
| Computational Biology | 2 | 2021 | 870 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2011 | 60 | 0.100 |
Why?
|
| Subtilisins | 2 | 2004 | 11 | 0.100 |
Why?
|
| Female | 13 | 2025 | 70720 | 0.100 |
Why?
|
| Carcinoma, Papillary | 2 | 2013 | 92 | 0.100 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 4683 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2014 | 230 | 0.100 |
Why?
|
| Caspase 8 | 1 | 2013 | 26 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2022 | 114 | 0.100 |
Why?
|
| Cathepsins | 2 | 2003 | 26 | 0.100 |
Why?
|
| Glucose | 2 | 2023 | 853 | 0.100 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2012 | 2 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 105 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2013 | 92 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 917 | 0.100 |
Why?
|
| Tumor Burden | 4 | 2017 | 241 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2011 | 294 | 0.090 |
Why?
|
| Point Mutation | 1 | 2013 | 332 | 0.090 |
Why?
|
| Smoking | 2 | 2014 | 931 | 0.090 |
Why?
|
| F-Box Proteins | 1 | 2011 | 32 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 201 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 4 | 2017 | 969 | 0.090 |
Why?
|
| Carrier Proteins | 3 | 2005 | 1018 | 0.080 |
Why?
|
| Mucous Membrane | 1 | 2011 | 89 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2021 | 27 | 0.080 |
Why?
|
| Diphenylamine | 1 | 2010 | 5 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2011 | 112 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 104 | 0.080 |
Why?
|
| Neoplasms | 2 | 2022 | 2964 | 0.080 |
Why?
|
| Phenotype | 5 | 2022 | 4484 | 0.080 |
Why?
|
| Cell Line | 4 | 2015 | 2573 | 0.080 |
Why?
|
| Benzamides | 1 | 2010 | 125 | 0.080 |
Why?
|
| Exome | 1 | 2014 | 1076 | 0.080 |
Why?
|
| Glutamine | 1 | 2011 | 204 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 1314 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1598 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1846 | 0.070 |
Why?
|
| Precision Medicine | 2 | 2023 | 382 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 361 | 0.070 |
Why?
|
| Subcellular Fractions | 2 | 2005 | 88 | 0.070 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 788 | 0.070 |
Why?
|
| Genes, p53 | 3 | 2015 | 211 | 0.070 |
Why?
|
| Pregnancy Trimester, First | 1 | 2008 | 119 | 0.070 |
Why?
|
| Aged | 2 | 2024 | 21005 | 0.060 |
Why?
|
| DNA Repair | 2 | 2021 | 581 | 0.060 |
Why?
|
| Middle Aged | 3 | 2024 | 28553 | 0.060 |
Why?
|
| Trophoblasts | 1 | 2008 | 116 | 0.060 |
Why?
|
| Disulfides | 2 | 2004 | 60 | 0.060 |
Why?
|
| Transfection | 3 | 2017 | 948 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 417 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 379 | 0.060 |
Why?
|
| DNA Replication | 2 | 2017 | 357 | 0.060 |
Why?
|
| Gene Expression | 3 | 2019 | 1494 | 0.060 |
Why?
|
| Protein Sorting Signals | 1 | 2005 | 43 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2004 | 48 | 0.050 |
Why?
|
| Adult | 2 | 2024 | 31296 | 0.050 |
Why?
|
| Smoke | 1 | 2025 | 81 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2005 | 2558 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2021 | 597 | 0.050 |
Why?
|
| Trypsin | 1 | 2004 | 66 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2939 | 0.050 |
Why?
|
| Cornea | 2 | 2005 | 561 | 0.050 |
Why?
|
| Cellular Reprogramming | 1 | 2025 | 128 | 0.050 |
Why?
|
| Genotype | 2 | 2022 | 2611 | 0.050 |
Why?
|
| CpG Islands | 2 | 2015 | 344 | 0.050 |
Why?
|
| Placenta | 1 | 2008 | 514 | 0.050 |
Why?
|
| Pancreatic Elastase | 1 | 2003 | 12 | 0.050 |
Why?
|
| Fibrinolysin | 1 | 2003 | 10 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2008 | 771 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2015 | 85 | 0.050 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 10 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2022 | 21 | 0.050 |
Why?
|
| Aurora Kinases | 1 | 2022 | 26 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 147 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2003 | 85 | 0.050 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2022 | 83 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2022 | 78 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 110 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2022 | 34 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 183 | 0.040 |
Why?
|
| Radiobiology | 1 | 2021 | 3 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 187 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 82 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1418 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2022 | 156 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 183 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3417 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2022 | 226 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 251 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2008 | 2442 | 0.040 |
Why?
|
| Serine Peptidase Inhibitor Kazal-Type 5 | 3 | 2005 | 6 | 0.040 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 3 | 2005 | 9 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2008 | 3487 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2025 | 806 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 479 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 41 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 1949 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2025 | 2344 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2022 | 747 | 0.040 |
Why?
|
| Cell Survival | 1 | 2021 | 843 | 0.040 |
Why?
|
| Kidney | 1 | 2005 | 1287 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 1728 | 0.030 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 171 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 772 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 2123 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 30 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2017 | 87 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2017 | 58 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 586 | 0.030 |
Why?
|
| Gene Editing | 1 | 2019 | 227 | 0.030 |
Why?
|
| ras Proteins | 1 | 2017 | 146 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 191 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 316 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2005 | 2397 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 4716 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 521 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 493 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 80 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2014 | 36 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 1006 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 157 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2014 | 16 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2014 | 16 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 75 | 0.030 |
Why?
|
| Insecta | 2 | 2004 | 50 | 0.030 |
Why?
|
| Time Factors | 2 | 2017 | 6231 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 421 | 0.020 |
Why?
|
| Skin | 1 | 2016 | 545 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 901 | 0.020 |
Why?
|
| Spodoptera | 2 | 2003 | 28 | 0.020 |
Why?
|
| Dasatinib | 1 | 2013 | 53 | 0.020 |
Why?
|
| Cell Line, Transformed | 2 | 2003 | 159 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 270 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 631 | 0.020 |
Why?
|
| Karyotype | 1 | 2012 | 30 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 110 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2012 | 135 | 0.020 |
Why?
|
| Cell Shape | 1 | 2012 | 68 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 80 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1079 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 654 | 0.020 |
Why?
|
| Indoles | 1 | 2013 | 201 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 359 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2004 | 715 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 517 | 0.020 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2011 | 20 | 0.020 |
Why?
|
| Base Sequence | 2 | 2008 | 2746 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 824 | 0.020 |
Why?
|
| INDEL Mutation | 1 | 2011 | 93 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 24 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 296 | 0.020 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2011 | 19 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2011 | 41 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 119 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 140 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 163 | 0.020 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2010 | 13 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 291 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 131 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 691 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2011 | 116 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2010 | 46 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2011 | 149 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 423 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 263 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 239 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 439 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 604 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 364 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 169 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 763 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 772 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 219 | 0.020 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2008 | 4 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2010 | 244 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1135 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2008 | 124 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2851 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 241 | 0.020 |
Why?
|
| Metabolomics | 1 | 2011 | 502 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 934 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5246 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2005 | 63 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 2145 | 0.010 |
Why?
|
| Microcirculation | 1 | 2005 | 108 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 5100 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 296 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 53 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2004 | 64 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 2004 | 48 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 254 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2005 | 407 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 557 | 0.010 |
Why?
|
| Trypsin Inhibitors | 1 | 2003 | 2 | 0.010 |
Why?
|
| Cathepsin G | 1 | 2003 | 3 | 0.010 |
Why?
|
| alpha-Amylases | 1 | 2003 | 10 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2003 | 13 | 0.010 |
Why?
|
| Chymotrypsin | 1 | 2003 | 12 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2004 | 141 | 0.010 |
Why?
|
| Cathepsin K | 1 | 2003 | 3 | 0.010 |
Why?
|
| Cathepsin L | 1 | 2003 | 9 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2003 | 15 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 64 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 467 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1391 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 11022 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 279 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 432 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 603 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2003 | 191 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 197 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 868 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 435 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 770 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 1087 | 0.010 |
Why?
|
| Lysosomes | 1 | 2003 | 269 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 1214 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 901 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 1458 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 3420 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3868 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 7500 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 12956 | 0.010 |
Why?
|